A substantial proportion of randomized clinical trials (RCTs) initially presented in conference proceedings are not published as full articles afterward.1,2 For example, a survey of 510 large phase 3 RCTs presented at American Society of Clinical Oncology (ASCO) annual meetings over 10 years found that 26% of them were not published.1 Thus, a meeting abstract may provide the only permanent information about an RCT that had been executed. The 2008 Consolidated Standards of Reporting Trials (CONSORT) for Abstracts defined a minimum list of essential items to include when reporting RCTs in abstracts.3 Herein, we assess the quality of ASCO abstracts of RCTs based on the CONSORT guidelines.
Xu Liu, Yu-Pei Chen, Wen-Fei Li, Ying Sun, Ying Guo, Avraham Eisbruch, Jun Ma. Quality of Abstracts Reporting Randomized Clinical Trials Presented at a Major Oncology Conference. JAMA Oncol. 2017;3(3):414–416. doi:10.1001/jamaoncol.2016.4899